Omega 3 fatty acids in patients infected by COVID-19

Nutraveris

In this double-blind, randomized clinical trial, 128 critically ill patients (35-85 years) infected with COVID-19 have been randomly assigned to the intervention (fortified formula with omega 3 fatty acids) (n = 42) and control (n = 86) groups during 14 days. The intervention group received one capsule of 1000 mg omega-3 daily containing 400 mg EPAs and 200 mg DHAs for 14 days through adding the supplement to their enteral formula.

The intervention group had significantly higher 1-month survival rate (21% vs. 3%, p = 0.003). Moreover, results showed that omega-3 supplementation improved the levels of several parameters of respiratory and renal function (higher levels of arterial pH, HCO3 and base excess, and lower levels of blood urea nitrogen, creatinine, and potassium) in critically ill patients with COVID-19.

Therefore, an omega 3 fatty acid supplementation may be effective for reducing the severity of COVID-19 infection.

Doaei S, Gholami S, Rastgoo S, Gholamalizadeh M, Bourbour F, Bagheri SE, Samipoor F, Akbari ME, Shadnoush M, Ghorat F, Mosavi Jarrahi SA, Ashouri Mirsadeghi N, Hajipour A, Joola P, Moslem A, Goodarzi MO. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. J Transl Med. 2021 Mar 29;19(1):128.

Photo by Pille-Riin Priske on Unsplash

NOL Data Solution
NOL Compliance